Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01064466 · ClinicalTrials.gov registry record · Phase 2
Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms
A Phase 2 study of Small-cell Lung Cancer, sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair.
- Active
- Registry status
- Phase 2
- Development phase
- 600
- Enrollment target
- 1
- Study location
NCT01064466: Active Phase 2 study of Small-cell Lung Cancer, sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair.
NCT01064466 is a Phase 2 study of Small-cell Lung Cancer that is active but no longer recruiting, run by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair. The registered enrollment target is 600 participants, above the 225-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (167% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01064466, a Phase 2 study of Small-cell Lung Cancer, is active but no longer recruiting, sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
Explore the relationship between drug target topoisomerase II gene single nucleotide polymorphisms and Etoposide (VP-16) therapeutic-effects in patients with small cell lung cancer, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target CYP4503A4 gene single nucleotide polymorphisms and Etoposide (VP-16) side-effects in patients with small cell lung cancer, based on Oxford precisely sequencing drug targets' genes.
Primary Outcome
1. Recruit 300 double blind random group separated SCLC patients currently used the Chemotherapy on Etoposide Capsule after lung tissue biopsy, like as the usual approach group. 2. Recruit 300 double blind random group separated SCLC patients currently used the Chemotherapy on China Import Etoposide Capsule after lung tissue biopsy, like as the study approach group. 3. Assay above every SCLC patient-specific Etoposide (VP-16) drug target (Topoisomerase II) SNP genotype in his or her WBC cell who
Conditions Studied
Interventions
- DRUG ETOPOSIDE - Usual
- DRUG ETOPOSIDE - Study
Study Locations (1)
Maryland
- Medicine Invention Design, Inc. (MIDI) - IORG0007849 - NPI 1023387701 - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2025-07-16 |
| Est. Completion | 2026-12-28 |
| Phase | Phase 2 |
What the registry record for NCT01064466 still lists
NCT01064466 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 225-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (167% higher).
The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which ETOPOSIDE - Usual is the first listed.
NCT01064466 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01064466 about?
NCT01064466 is a clinical study titled "Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms". Explore the relationship between drug target topoisomerase II gene single nucleotide polymorphisms and Etoposide (VP-16) therapeutic-effects in patients with small cell lung cancer, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target CYP4503A4 gene...
What is the current status of trial NCT01064466?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 600 participants. The study started on 2025-07-16. Estimated completion is 2026-12-28.
What conditions does trial NCT01064466 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer.
What interventions are being tested in trial NCT01064466?
The interventions under investigation include: ETOPOSIDE - Usual (DRUG), ETOPOSIDE - Study (DRUG).
Who is sponsoring clinical trial NCT01064466?
This trial is sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01064466 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01064466's enrollment target sits among peer trials
600 8th of 79 higher than 72 of 79 other Small-cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
RECRUITING · Phase 2
-
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
RECRUITING · Phase 2
-
Study of Trilaciclib and Lurbinectidin
RECRUITING · Phase 2
-
Phase 2 Study of Fingolimod in Lung Cancers
RECRUITING · Phase 2
-
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
RECRUITING · Phase 2
-
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI